Search Results for "prepared"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for prepared. Results 11 to 20 of 47 total matches.

Idecabtagene Vicleucel (Abecma) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
is an individualized cellular product prepared from the patient’s own T cells, which are genetically modified ...
The FDA has approved idecabtagene vicleucel (Abecma – BMS), a B-cell maturation antigen (BCMA)-directed genetically-modified cellular product, for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Abecma is an individualized cellular product prepared from the patient’s own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. Ciltacabtagene autoleucel...
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e190-1 |  Show IntroductionHide Introduction

Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021  (Issue 1639)
with ophthalmic preparations used for treatment of dry eye disease are available. ADVERSE EFFECTS — The most ...
Tyrvaya (Oyster Point), a nasal spray formulation of the cholinergic agonist varenicline, has been approved by the FDA for treatment of dry eye disease. It is the first nasal spray to be approved in the US for this indication. An oral formulation of varenicline (Chantix, and generics) has been available for years for smoking cessation.
Med Lett Drugs Ther. 2021 Dec 13;63(1639):198-9 |  Show IntroductionHide Introduction

A New Indication for Axicabtagene Ciloleucel (Yescarta) (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
prepared from the patient's own T cells, which are genetically modified to express chimeric antigen ...
The FDA recently approved axicabtagene ciloleucel (Yescarta – Kite), a CD19-directed genetically modified cellular product, for treatment of large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line treatment. It was previously approved for treatment of relapsed or refractory B-cell lymphoma after ≥2 lines of systemic therapy and for treatment of relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. Yescarta is an individualized cellular product prepared from the patient's own T cells,...
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e194-5 |  Show IntroductionHide Introduction

In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
after ≥2 lines of systemic therapy. Breyanzi is an individualized cellular product prepared ...
The FDA has approved lisocabtagene maraleucel (Breyanzi – BMS) for treatment of adults with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, or follicular lymphoma grade 3B who have disease refractory to first-line chemoimmunotherapy, relapsed within 12 months of or after first-line chemoimmunotherapy, are not eligible for hematopoietic stem cell transplantation due to comorbidities or age, or have relapsed or refractory disease after ≥2 lines of...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e104-5   doi:10.58347/tml.2023.1679f |  Show IntroductionHide Introduction

Ciltacabtagene Autoleucel (Carvykti) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
antibody. Carvykti is an individualized cellular product prepared from the patient's own T cells, which ...
The FDA has approved ciltacabtagene autoleucel (Carvykti – Janssen), a B-cell maturation antigen (BCMA)-directed genetically-modified cellular product, for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Carvykti is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. Idecabtagene...
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e188-9 |  Show IntroductionHide Introduction

Vyalev — Foscarbidopa/Foslevodopa Subcutaneous Infusion for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025  (Issue 1719)
vials containing 120 mg of foscarbidopa and 2400 mg of foslevodopa. Preparation for administration ...
Vyalev (Abbvie), a solution for continuous subcutaneous infusion containing the prodrugs foscarbidopa and foslevodopa, has been approved by the FDA for treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Vyalev is the first subcutaneously administered product to become available in the US for treatment of PD symptoms. Duopa, a carbidopa/levodopa enteral suspension infused via a nasojejunal tube or percutaneous gastrostomy, was approved in for the same indication 2015.
Med Lett Drugs Ther. 2025 Jan 6;67(1719):7-8   doi:10.58347/tml.2025.1719c |  Show IntroductionHide Introduction

An EUA for Casirivimab and Imdevimab for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
minutes before dose preparation. The two antibodies are only authorized for administration together ...
The FDA has issued an Emergency Use Authorization (EUA) for Regeneron's investigational monoclonal antibodies casirivimab and imdevimab (REGEN-COV) to be administered together by IV infusion or SC injection for treatment of mild to moderate COVID-19 in adults and pediatric patients (≥12 years old and weigh ≥40 kg) who are at high risk of progressing to severe COVID-19 and/or hospitalization.
Med Lett Drugs Ther. 2020 Dec 28;62(1614):201-2 |  Show IntroductionHide Introduction

Relyvrio for ALS

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022  (Issue 1664)
within 1 hour of preparation. The suspension can be taken orally or via feeding tube. The recommended ...
The FDA has approved Relyvrio (Amylyx), a fixed-dose combination of sodium phenylbutyrate and taurursodiol, for treatment of amyotrophic lateral sclerosis (ALS). Sodium phenylbutyrate (Buphenyl, and others) has been available by prescription for years for treatment of urea cycle disorders. Taurursodiol (tauroursodeoxycholic acid), a derivative of ursodiol, is an over-the-counter bile acid supplement claimed to have neuroprotective benefits. Relyvrio is the third drug to be approved in the US for treatment of ALS; riluzole (Rilutek, and others) and edaravone (Radicava, Radicava...
Med Lett Drugs Ther. 2022 Nov 28;64(1664):190-1 |  Show IntroductionHide Introduction

Table: Correct Use of Inhalers for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 07, 2020  (Issue 1606)
Prepare the dose by sliding the lever next to the mouthpiece away from you until it clicks Exhale fully ...
View the Table: Correct Use of Inhalers for COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e150-4 |  Show IntroductionHide Introduction

In Brief: Obecabtagene Autoleucel (Aucatzyl) - Another CAR-T Cell Immunotherapy for ALL (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024  (Issue 1718)
is an individualized cellular product prepared from the patient’s own T cells, which are genetically modified ...
Obecabtagene autoleucel (Aucatzyl – Autolus), a CD19-directed genetically modified autologous T cell immunotherapy, has been approved by the FDA for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. The CAR T-cell immunotherapy products tisagenlecleucel (Kymriah) and brexucabtagene auto-leucel (Tecartus) were approved earlier for the same indication.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):e208   doi:10.58347/tml.2024.1718f |  Show IntroductionHide Introduction